Alzheimer Disease and Dementia

Latest News

Stepwise Approach Effective for Primary Care Dementia Screening

Assessment of dementia risk using three common screening tools at baseline predicts incident dementia over the course of about seven years.

Migraine Linked to Higher Risk for Dementia, Alzheimer Disease

Migraines are a significant risk factor for Alzheimer disease (AD) and all-cause dementia.

Brain Changes Differ for β-Amyloid, Cerebrovascular Burden

β-amyloid (Aβ) and cerebrovascular disease burden have divergent effects on longitudinal default mode network and executive control network functional connectivity changes in amnestic MCI and subcortical vascular MCI.

Majority of Those Diagnosed With Dementia Do Not Receive Care From Specialist

The majority of older adults diagnosed with dementia do not receive specialty care.

Hydroxychloroquine Use Not Linked With Risk for Alzheimer Disease

Investigators addressed the association between long-term use of hydroxychloroquine therapy and the risk for Alzheimer disease.

Trials Investigating Elenbecestat in Early Alzheimer Disease Discontinued

Results of a safety review have led to the discontinuation of phase 3 clinical studies of elenbecestat, an investigational oral BACE (beta amyloid cleaving enzyme) inhibitor, which was being assessed for early Alzheimer disease (AD) treatment.

Imaging Technique May Help Predict Stroke-Related Dementia

Diffusion tensor image segmentation technique, which characterizes microstructural damage across the cerebellum, identifies damage in cerebral small vessel disease and can predict dementia.

Improving Delirium Detection in the Acute Setting: An Expert Interview

Delirium is highly prevalent in critical care, especially among elderly patients and individuals with dementia. Although rates vary widely across studies, findings suggest delirium affects more than 15% of hospitalized patients. For additional discussion regarding this topic, Neurology Advisor interviewed Leopoldo Pozuelo, MD, MBA, FACP, FACLP, clinical vice chair of psychiatry and psychology at the Cleveland Clinic in Ohio.

Lack of Evidence for Cognitive Screening in Older Adults, According to USPSTF

The USPSTF concludes that the evidence is currently inadequate for weighing the benefits and harms of screening for cognitive impairment among older adults.

Trial Investigating Pimavanserin for Dementia-Related Psychosis Stopped Early Due to Positive Finding

A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.